Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis

Blood - Tập 128 Số 12 - Trang 1609-1613 - 2016
Gabriela Mladonická Pavlasová1,2, Marek Borský2, Václav Šeda1,2, Kateřina Amruz Černá1,2, Jitka Osičková2, Michael Doubek2, Jiřı́ Mayer2, Raffaele Calogero3, Martin Trbušek2, Šárka Pospı́šilová2, Matthew S. Davids4, Thomas J. Kipps5, Jennifer R. Brown4, Marek Mráz1,2
1Central European Institute of Technology, Masaryk University, Brno, Czech Republic
2Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
3Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy;
4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and
5Moores Cancer Center, Department of Medicine, University of California San Diego, La Jolla, CA

Tóm tắt

Key Points Microenvironmental interactions upregulate CD20 expression in CLL cells through the CXCR4/SDF-1 axis. Ibrutinib treatment causes downregulation of CD20 in CLL cells.

Từ khóa


Tài liệu tham khảo

Byrd, 2013, Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia., N Engl J Med, 369, 32, 10.1056/NEJMoa1215637

Furman, 2014, Idelalisib and rituximab in relapsed chronic lymphocytic leukemia., N Engl J Med, 370, 997, 10.1056/NEJMoa1315226

de Rooij, 2012, The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia., Blood, 119, 2590, 10.1182/blood-2011-11-390989

Ponader, 2012, The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo., Blood, 119, 1182, 10.1182/blood-2011-10-386417

Seda, 2015, B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells., Eur J Haematol, 94, 193, 10.1111/ejh.12427

Chen, 2016, BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia., Leukemia, 30, 833, 10.1038/leu.2015.316

Burger, 2014, Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study., Lancet Oncol, 15, 1090, 10.1016/S1470-2045(14)70335-3

Herman, 2014, Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study., Leukemia, 28, 2188, 10.1038/leu.2014.122

O’Brien, 2015, A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia., Blood, 126, 2686, 10.1182/blood-2015-03-630947

Buchner, 2010, The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies., Br J Haematol, 151, 167, 10.1111/j.1365-2141.2010.08316.x

Mraz, 2011, Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance., Br J Haematol, 155, 53, 10.1111/j.1365-2141.2011.08794.x

Marquez, 2015, Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL., Br J Haematol, 169, 211, 10.1111/bjh.13286

Lwin, 2007, Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin’s lymphoma cells., Leukemia, 21, 1521, 10.1038/sj.leu.2404723

Skarzynski, 2016, Interactions between ibrutinib and anti-CD20 antibodies: competing effects on the outcome of combination therapy., Clin Cancer Res, 22, 86, 10.1158/1078-0432.CCR-15-1304

Calissano, 2011, Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells., Mol Med, 17, 1374, 10.2119/molmed.2011.00360

Cui, 2014, MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia., Blood, 124, 546, 10.1182/blood-2014-03-559690

Hussain, 2007, Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity., Clin Cancer Res, 13, 2144, 10.1158/1078-0432.CCR-06-2294

Byrd, 2002, The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction., Blood, 99, 1038, 10.1182/blood.V99.3.1038

Petrie, 2002, Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts., J Immunol, 169, 2886, 10.4049/jimmunol.169.6.2886

Uchida, 2004, Mouse CD20 expression and function., Int Immunol, 16, 119, 10.1093/intimm/dxh009

Polyak, 2008, CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins., J Biol Chem, 283, 18545, 10.1074/jbc.M800784200

Franke, 2011, Antibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell lines., PLoS One, 6, e16596, 10.1371/journal.pone.0016596

Mraz, 2014, miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1., Blood, 124, 84, 10.1182/blood-2013-09-527234

Musilova, 2015, MicroRNAs in B-cell lymphomas: how a complex biology gets more complex., Leukemia, 29, 1004, 10.1038/leu.2014.351

Thông tin
Thông tin xuất bản

Blood

Tập 128 Số 12

1609-1613

Thông tin tác giả